December, 2022

article thumbnail

From chemistry to canvas: What the pharma world can learn from art

PharmaVoice

Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work.

Pharma 110
article thumbnail

Pfizer, Sanofi settle first California Zantac case slated for trial: report

Fierce Pharma

Pfizer, Sanofi settle first California Zantac case slated for trial: report. zbecker. Thu, 12/22/2022 - 12:38.

346
346
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Non-toxic and addiction free: The promise of a new pain med

PharmaVoice

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

Pharma 122
article thumbnail

Camera Measures Blood Pressure with Quick Look

Medgadget

At the University of South Australia, researchers designed a system that allows them to measure a patient’s blood pressure with a camera. The camera visualizes the patient’s forehead and focuses on two regions in particular to optically determine photoplethysmographic signals that AI algorithms then convert to blood pressure data. The researchers tested their system in 25 volunteers, and so far it has proven to be approximately 90% as accurate as traditional pressure cuff measurements.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

UK digital health project aims to tackle dysfunctional breathing

pharmaphorum

A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population. The Engineering and Physical Sciences Research Council (EPSRC) has set aside £400,000 (almost $490,000) for the project, which will help fund work at the Universities of Plymouth, Salford and Stirling, and the Glasgow School of Art.

Patients 145
article thumbnail

The Boston Globe Names CCC a Top Place to Work for 2022

Copyright Clearance Center

December 13, 20 22 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, has been named one of the Top Places to Work in Massachusetts in the 15 th annual employee-based survey project from The Boston Globe. CCC ranked #17, up from #33 last year, in the “ large companies ” category (organizations between 250-999 employees).

More Trending

article thumbnail

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Fierce Pharma

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report. aarmstrong. Thu, 12/29/2022 - 14:42.

FDA 314
article thumbnail

Here’s How Skilled Nursing Facilities Can Use Virtual Reality Too

MedCity News

It may take some time to introduce VR into your skilled nursing facility, but it will be worth it for the physical, mental, and social benefit of your residents.

Training 145
article thumbnail

Moderna finalises plans for UK mRNA vaccine manufacturing centre

European Pharmaceutical Review

Moderna, Inc. has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK Government, announced in June 2022. The Moderna Innovation and Technology Centre (MITC) is intended to provide access to a UK-made supply of COVID-19 jabs.

article thumbnail

Four ways Biogen is tackling digital innovation in neurological disease

pharmaphorum

Digital transformation in pharma is not a singular endeavour. It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations.

Patients 137
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Belt Monitors Heart Failure Patients

Medgadget

Researchers at Florida Atlantic University have developed a belt that can monitor heart failure patients for signs of disease progression. The wearable device measures heart rate, thoracic impedance, electrocardiogram, and motion, all of which can provide information on a heart failure patient’s status and potentially enable early detection of disease exacerbation.

Patients 120
article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Medicine 131
article thumbnail

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard

Fierce Pharma

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard. aliu. Tue, 12/13/2022 - 20:12.

318
318
article thumbnail

7 Strategies for Integrating Behavioral Health Into Primary Care

MedCity News

As we collectively address this rising tide of behavioral health needs, we will need more payment reform, more innovation, and continued migration to more prospective payment models and treatment approaches that bring all stakeholders together to care for patients in a holistic manner.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Could ketamine-assisted therapy help treat alcoholism?

European Pharmaceutical Review

A new £2.4 million Phase III trial will determine if ketamine-assisted therapy can help those with severe alcohol use disorder to stay off alcohol for longer. Led by the University of Exeter and funded by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), “[t]his is the largest trial of its kind in the world and builds on our earlier, smaller positive trial,” stated Professor Anne Lingford-Hughes, Professor of Addiction Biology at Imperial College

article thumbnail

Investigation launched into alleged animal welfare violations at Neuralink

pharmaphorum

Elon Musk’s brain computer interface (BCI) company Neuralink is being investigated by law enforcement authorities in the US amid allegations of animal welfare violations in its testing facilities. Neuralink’s BCI is intended to treat conditions like blindness and spinal cord injury, as well as provide a way to interact with digital devices using the brain and, according to Musk, is on the brink of moving into the human testing stage.

article thumbnail

2023 Pipeline Report: Testing the Limits

PharmExec

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

119
119
article thumbnail

Looking back at 2022: The top healthcare stories

Pharmaceutical Technology

The healthcare industry saw its share of ups and downs in 2022. Our response to the worldwide pandemic evolved over time, and so did the needs of the sector and the people relying on healthcare companies to deliver solutions. Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo

Fierce Pharma

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo. fkansteiner. Mon, 12/19/2022 - 14:06.

309
309
article thumbnail

By Eliminating Requirement for Animal Testing, FDA Modernization Act Allows Faster, More Cost-effective Drug Development

MedCity News

By easing regulatory requirements for animal testing, the Act allows scientists to use innovative, leading-edge technologies more fully in future drug development strategies. .

FDA 132
article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Fluoxetine was approved to treat depression 35 years ago. Since then, there have been few breakthrough innovations in treating neuropsychiatric diseases such as anxiety, depression, substance use disorders (SUDs), and post-traumatic stress disorder (PTSD). For many indications, progress has been incremental. Psychedelic research, in particular, is gaining momentum. .

article thumbnail

UK, Moderna formalise 10-year vaccines alliance

pharmaphorum

Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna. The government said today it has finalised the partnership – agreed in principle earlier this year and estimated to be worth in the region of $1.2 billion – although it is not revealing the financial details, as these are “commercially sensitive.” The overar

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Female Board Members Are Good for Business

PharmExec

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

136
136
article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

Kite Pharma and Daiichi Sankyo have updated a partnership agreement signed in 2017 for the former’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. Subsequently, in the same year, Gilead Sciences acquired Kite.

article thumbnail

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Fierce Pharma

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead. aliu. Fri, 12/09/2022 - 09:15.

307
307
article thumbnail

How “Lung Intelligence” is Accelerating New Therapies

MedCity News

Thanks to the convergence of cloud technologies, AI, and refined lung data, we are in a new era for those with chronic lung disease. In this new world, lung intelligence provides fast, precision measures of treatment efficacy so new drugs can blaze through the trial pipeline.

Biopharma 132
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

mRNA therapeutics: a limitless revolution in medicine

European Pharmaceutical Review

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. mRNA technologies have emerged as an innovative and effective approach to developing new drugs that can potentially transform existing therapies or target difficult‑to‑treat indications including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer.

Medicine 116
article thumbnail

CSL closes on EU approval for haemophilia B gene therapy

pharmaphorum

CSL’s gene therapy for haemophilia B has been recommended for approval by the EMA’s human medicine committee, setting up a decision by the European Commission early next year. The positive opinion for etranacogene dezaparvovec – which was approved as Hemgenix by the FDA last month – raises the prospect of the first one-time therapy in the EU for the bleeding disorder, which affects around 1 in 50,000 of the population, according to the European Haemophilia Network (EUHANET).

Medicine 125
article thumbnail

Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai

Pharmatutor

Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai. admin. Sat, 12/10/2022 - 15:42. Academically.ai, We are an Australian healthcare education technology (EdTech) start-up based in Sydney. We provide courses that will prepare pharmacists to practice, getting a job and migrate to Australia and New Zealand. To put it simply, we intend to enter the Indian market because the majority of pharmacists are underpaid, and many are unaware of such vast potential outsid

Education 111
article thumbnail

EMA CHMP recommends Moderna’s Covid-19 booster for children

Pharmaceutical Technology

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting variation to the marketing authorization (MA) for Moderna ’s Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214) booster for usage in children aged six to 11 years. The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination.

Medicine 121
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A